Company release No. 16/2024
ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited)
Revenue growth was driven by a continued strong momentum in tablet sales, and improved performance of injection- and drop-based allergy immunotherapy products. ALK's European and International markets were key contributors to growth. The increase in operating profit (EBIT) of 189% is in-line with ALK's financial targets. Full-year outlook has been upgraded.
Q2 performance highlights
Comparative figures for Q2 2023 are shown in brackets. Revenue growth rates are stated in local currencies, unless otherwise indicated.
Total revenue increased by 21% in local currencies to DKK 1,374 million (1,135) on broad-based growth.
Tablet sales were up 32% to DKK 716 million (547) on double-digit growth in all sales regions. Europe was a key contributor with 35% growth.
Combined SCIT and SLIT-drops sales grew by 16% to DKK 490 million (423) and saw robust growth in Europe and increasing SCIT shipments to China.
Sales of Other products and services increased by 1% to DKK 168 million (165). Jext® sales increased by 17% and is recovering from previous supply shortages while sales of other products declined.
Operating profit (EBIT) increased by 189% in local currencies to DKK 264 million (97), with an EBIT margin of 19% (9%). Progress was driven by sales growth, gross margin improvements, and prudent cost management leading to lower total costs to R&D, Sales & Marketing and Administration. EBIT included one-off costs of DKK 38 million (0) associated with previously announced optimisation initiatives.
Financial highlights
Growth
Growth
In DKKm
Q2 2024
l.c.
r.c.
